Mesa Laboratories (MLAB) Peer Comparison
$127.99
$-0.66
(-0.51%)
As on 28-Aug-2026 13:34EDT
Market cap
$698 Mln
Revenue (TTM)
$250 Mln
P/E Ratio
141.8
P/B Ratio
3.5
Div. Yield
0.5 %
Edit
| Mesa Laboratories (MLAB) | Penumbra (PEN) | Glaukos Corp (GKOS) | Repligen (RGEN) | Bio-Rad Laboratories | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
698 | 12,753 | 10,906 | 10,222 | 9,762 |
Revenue ($ Mln) |
250 | 1,505 | 613 | 785 | 2,589 |
Net Profit ($ Mln) |
4.80 | 160.59 | -188.05 | 41.54 | 222.40 |
Net Margin (%) |
1.92 | 10.67 | -30.68 | 5.29 | 8.59 |
RoE (%) |
2.56 | 10.86 | -28.10 | 1.97 | 3.04 |
Price to Earnings |
141.77 | 79.35 | -- | 251.57 | 44.47 |
Price-To-Book |
3.54 | 8.41 | 16.38 | 4.84 | 1.26 |
Income Statement ($ Mln)
| Mesa Laboratories (MLAB) | Penumbra (PEN) | Glaukos Corp (GKOS) | Repligen (RGEN) | Bio-Rad Laboratories | |
|---|---|---|---|---|---|
|
Operating Revenue
|
249.13 | 1,403.67 | 507.44 | 738.26 | 2,583.20 |
|
Cost of Revenue
|
90.86 | 461.23 | 114.23 | 390.63 | 1,239.60 |
|
Gross Profit
|
158.27 | 942.44 | 393.22 | 347.62 | 1,343.60 |
|
Operating Expenses
|
139.76 | 753.19 | 479.95 | 288.05 | 1,077.50 |
|
Operating Profit (EBIT)
|
18.51 | 189.25 | -86.73 | 59.58 | 270.50 |
|
Other Income
|
-- | -- | -- | -- | -- |
|
Profit before Tax
|
12.01 | 205.13 | -193.04 | 62.38 | 995.50 |
|
Provision for Tax
|
5.30 | 27.44 | -5.35 | 13.49 | 235.60 |
|
Profit after Tax (Net Income)
|
6.71 | 177.69 | -187.69 | 48.89 | 759.90 |
|
Minority Interest
|
-- | -- | -- | -- | -- |
|
Consolidated Profit
|
-- | 177.69 | -- | -- | -- |
Liabilities ($ Mln)
| Mesa Laboratories (MLAB) | Penumbra (PEN) | Glaukos Corp (GKOS) | Repligen (RGEN) | Bio-Rad Laboratories | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
186.25 | 1,427.60 | 656.16 | 2,106.13 | 7,453.60 |
|
Minority Interest
|
-- | -- | -- | -- | -- |
|
Non-Current Liabilities
|
179.60 | 215.78 | 136.06 | 707.74 | 2,605.90 |
|
Current Liabilities
|
61.90 | 183.13 | 101.28 | 135.83 | 517.00 |
|
Total Liabilities
|
427.75 | 1,826.52 | 893.49 | 2,949.70 | 10,576.50 |
Assets ($ Mln)
| Mesa Laboratories (MLAB) | Penumbra (PEN) | Glaukos Corp (GKOS) | Repligen (RGEN) | Bio-Rad Laboratories | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
321.48 | 609.84 | 418.50 | 1,812.31 | 7,670.30 |
|
Current Assets
|
106.27 | 1,216.68 | 474.98 | 1,137.39 | 2,906.20 |
|
Total Assets
|
427.75 | 1,826.52 | 893.49 | 2,949.70 | 10,576.50 |
|
Total Debt*
|
168.83 | 219.70 | 139.64 | 689.95 | 1,531.00 |
|
Net Current Assets
|
44.37 | 1,033.55 | 373.71 | 1,001.56 | 2,389.20 |
Cashflow ($ Mln)
| Mesa Laboratories (MLAB) | Penumbra (PEN) | Glaukos Corp (GKOS) | Repligen (RGEN) | Bio-Rad Laboratories | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
42.83 | 238.66 | -46.34 | 117.42 | 532.20 |
|
Cash Flow from Investing Activities
|
-3.25 | -404.59 | -77.61 | -298.47 | -189.70 |
|
Cash from Financing Activities
|
-41.85 | 26.53 | 11.89 | -15.21 | -283.20 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| Mesa Laboratories (MLAB) | Penumbra (PEN) | Glaukos Corp (GKOS) | Repligen (RGEN) | Bio-Rad Laboratories | |
|---|---|---|---|---|---|
|
ROCE (%)
|
1.93 | 11.76 | -22.53 | 1.79 | 8.98 |
|
ROE (%)
|
3.88 | 13.78 | -26.38 | 2.40 | 10.84 |
|
ROA (%)
|
1.56 | 10.58 | -20.09 | 1.69 | 7.62 |
|
EBIT Margin (%)
|
-- | -- | -- | -- | -- |
|
Net Margin (%)
|
2.69 | 12.66 | -36.99 | 6.62 | 29.42 |
|
Cash Profit Margin (%)
|
-- | -- | -- | -- | -- |
Growth Ratios
| Mesa Laboratories (MLAB) | Penumbra (PEN) | Glaukos Corp (GKOS) | Repligen (RGEN) | Bio-Rad Laboratories | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
0.03 | 0.17 | 0.32 | 0.16 | 0.01 |
|
EBIT Growth (%)
|
-- | -- | -- | -- | -- |
|
Net Profit Growth (%)
|
440.02 | 1,168.11 | -28.23 | 291.64 | 141.20 |
|
EPS Growth (%)
|
4.33 | 11.64 | -0.24 | 2.90 | 1.43 |
|
Book Value Growth (%)
|
-- | -- | -- | -- | -- |
Valuation Ratios
| Mesa Laboratories (MLAB) | Penumbra (PEN) | Glaukos Corp (GKOS) | Repligen (RGEN) | Bio-Rad Laboratories | |
|---|---|---|---|---|---|
|
Price / Earnings
|
73.03 | 68.93 | -34.59 | 189.42 | -- |
|
Price / Book Value
|
2.63 | 8.58 | 9.90 | 4.40 | -- |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
17.91 | 53.25 | -43.50 | 55.90 | -- |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Mesa Laboratories (MLAB) | Penumbra (PEN) | Glaukos Corp (GKOS) | Repligen (RGEN) | Bio-Rad Laboratories | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.91 | 0.15 | 0.21 | 0.33 | 0.21 |
|
Short term debt to equity ratio
|
0.05 | 0.01 | -- | 0.01 | 0.01 |
|
Current Ratio
|
1.72 | 6.64 | 4.69 | 8.37 | 5.62 |
|
Quick Ratio
|
1.29 | 4.29 | 4.06 | 7.12 | 4.19 |
|
Interest Coverage
|
1.12 | 157.46 | -40.65 | 3.69 | 21.32 |
Operating Efficiency Ratios
| Mesa Laboratories (MLAB) | Penumbra (PEN) | Glaukos Corp (GKOS) | Repligen (RGEN) | Bio-Rad Laboratories | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
17.70 | 13.54 | 21.40 | 21.48 | 18.29 |
|
Asset Turnover
|
0.58 | 0.84 | 0.54 | 0.26 | 0.26 |
|
Receivable days
|
63.09 | 46.54 | 60.95 | 72.41 | 65.39 |
|
Inventory Days
|
103.99 | 331.92 | 193.84 | 146.53 | 221.09 |
|
Payable days
|
21.46 | 26.16 | 60.19 | 29.05 | 37.02 |
|
Cash Conversion Cycle
|
145.63 | 352.30 | 194.60 | 189.88 | 249.46 |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
